October 26, 2016 5:27pm

 

... As the share pricing reality defines the investor challenge to stay the course

 

Pre-market indication review:  2 hit and 2 miss …

 

 

I answer one question; in which company should investors put, keep and commit their money!

 

 

Do you care what happened today … because it has implications to Thursday's sector activity?   Your portfolio is the loser if not subscribed!

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 

U.S. stock closed mostly lower on Wednesday as earnings season continued, while solid economic data helped financials and oil extended its losing streak despite bullish supply data.

The NASDAQ closed DOWN -33.13 or -0.63% to 5,250.27 and the DOW closed DOWN -30.06 or -0.17% to 18,199.33.  

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

·         The open was neutral with an A/DL of 21/21 and 1 flat;

·         The mid-day slipped negative  with an A/DL of 14/27 and 2 flats;

·         The closing bell  was negative with A/DL of 14/28 and 1 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened neutral, slipped negative at the mid-day and closed negative.

  • The stem, cell, gene and regenerative therapy sector are feeling the “pain” of share pricing declines as financial results/earnings or loss-per-share (LPS) numbers are hitting the wires.

As I had stated this a.m. and last night’s post, “Technicals and support are weak as resistance strengthens.”

  • Trading pressures and negative share returns are depressing sentiment hampering any upside after four (4) down sessions to date!

I have been hoping there would be a respite or an opportunity for the upside to follow- through to address the oversold actions - wrong.

  • The iShares Russell 2000 (IWM) indicated a negative pre- open -0.74% and was DOWN -0.97% at the close while the iShares Nasdaq Biotechnology (IBB) indicated a negative pre-open -0.19% and closed +0.05%.

 

 

Look close at today and the past days – trading ranges - I see patterns:

The downside trend reflects a pricing trend range of:

·         Wednesday’s decliners ranged from -0.24% to -5.36% in 28 equities;

·         Tuesday’s decliners ranged from -0.20%  to -12.82% in 28 equities;

·         Monday’s decliners ranged from  -0.04% to -5.33% in 27 equities;

·         Friday’s decliners ranged from -0.24%  to -13.11% in 23 equities;

·         Thursday’s decliners ranged from -0.31% to -15.19% in 16 equities;

·         Last Wednesday’s decliners ranged from -0.29 to -7.69% in 27 equities;

 

The upside shows a pricing trend range of:

·         Wednesday’s advancers ranged from  +0.14% to +9.09%  in 14 equities

·         Tuesday’s advancers ranged from +0.31% to +7.89% in 9 equities

·         Monday’s advancers ranged from +0.26% to +27.04% in 10 equities;

·         Friday’s advancers ranged +0.24% to +4.26% in 17 equities;

·         Thursday’s upside ranged from +0.51% to +6.94% in 25 equities;

·         Last Wednesday’s upside ranged from +0.24% to 14.34% in 16 equities;

 

Wrap-up: Wednesday’s scoreboard <43 companies reporting> Wednesday’s gains 14 compared to Tuesday’s  9 gains decreasing from Monday’s 10 with increasing volume; while Wednesday’s downside of 28 compared to Tuesday’s 28 compared to Monday’s 27 with moderate volume.

 

 

Pre-market indication review:  2 hit and 2 miss …

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.15 – miss;
  • Biostage (BSTG) closed DOWN -$0.0343 – hit;
  • BioTime (NYSEMKT: BTX) closed DOWN -$0.11 – miss;
  • Spark Therapeutics (ONCE) closed UP +$0.11 – hit;

 

 

Wednesday, Tuesday, Monday and Friday were DOWN days, walking past a strong upside on last Thursday …

 

Percentage decliners:

·         Capricor (CAPR) -5.36%;

·         Verastem (VSTM) -4.65%;

·         Biostage (BSTG) -3.73% after Tuesday’s +5.31% or +$0.05;;

·         BioTime (NYSEMKT: BTX) -3.14%;

·         Opexa (OPXA) -2.76%;

 

Percentage advancers:

·         International Stem Cell (ISCO) +9.09%;

·         Fibrocell (FCSC) +8.80% after Tuesday’s -6.99%;

·         Cesca Therapeutics (KOOL) +5.88% after Tuesday’s -12.82% after Monday’s +27.04% after Friday’s +6.68%;

·         Brainstorm (BCLI) +5.56%;

·         ReNeuron (RENE.L) +5.226%;

 

 

Flat:                                                                                                      

·         Vericel (VCEL) at $2.35

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Wednesday traded near 14.6;

·         Tuesday traded near 13.6. The index was on track to snap a five-day losing streak;

·         Monday traded near 13;

·         Friday traded near 13.5;

·         Thursday traded near 13.9

·         Last Wednesday traded near 14.3;

                                                                                                              

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.